免疫检查点抑制剂在SMARCA4缺乏的非小细胞肺癌中有效性有限
Ying Han1, Jing Wang1, Boyue Pang1
1Key Laboratory of Cancer Immunology and Biotherapy, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China.
Translational lung cancer research
|December 10, 2025
概括
缺少SMARCA4的NSCLC预后不佳,对免疫检查点抑制剂的反应有限. STK11/KEAP1突变和SMARCA4功能丧失加剧了结果和免疫抑制.
科学领域:
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
- 免疫治疗是一种免疫疗法.
背景情况:
- 缺少SMARCA4的非小细胞肺癌 (SD-NSCLC) 具有攻击性,预后不佳.
- 在SD-NSCLC中免疫检查点抑制剂 (ICI) 的临床疗效需要进一步研究.
- 本研究使用TCGA数据库调查了ICI疗效,预后风险因素和SD-NSCLC中的机制.
研究的目的:
- 为了评估ICI在SD-NSCLC患者的疗效.
- 确定影响SD-NSCLC预后的风险因素.
- 探索SD-NSCLC和ICI反应背后的分子机制.
主要方法:
- 对95名SD-NSCLC患者的分析,这些患者于2020年10月至2025年5月接受治疗.
- 利用癌症基因组图谱 (TCGA) 数据库进行验证和机制探索.
- 主要终点:无疾病存活率 (DFS) 和无病变存活率 (PFS);次要终点:疾病控制率 (DCR).
主要成果:
- 在IV期SD-NSCLC中,ICI和非ICI组之间没有显著的PFS差异.
- 在STK11/KEAP1突变体和野生型组之间观察到显著的PFS差异,即使在ICI治疗中也是如此.
- SMARCA4功能丧失突变与较短的PFS相关,并表明免疫抑制.
结论:
- SMARCA4缺乏是NSCLC的一个独立预后因素.
- STK11/KEAP1共同突变使预后恶化,并可能影响治疗反应.
- 由于代谢障碍,瘤抑制剂失活和免疫抑制,SMARCA4缺乏导致免疫治疗反应不佳.
更多相关视频
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
11.0K
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
12.1K
相关概念视频
02:34Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K